Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl) methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS

被引:4
作者
Zhao, YP [1 ]
Sukbuntherng, J [1 ]
机构
[1] Sugen, Dept Bioanal & Phamarcokinet, San Francisco, CA USA
关键词
Z-isomer; E-isomer; LC/MS/MS; SU5416;
D O I
10.1016/j.jpba.2005.01.029
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Z-3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) is a cytostatic substance in development as an anti-angiogenic agent. SU5416 exists as the thermodynamically stable cis or Z-isomer as a solid. Studies have shown that in light exposed solutions of SU5416, the unstable trans or E-isomer, namely SU5886, is formed. The E-isomer converts back to the Z-isomer when protected from light. The E-isomer is unstable for synthesis and isolation; therefore, the analytical standard of the E-isomer is not available. In this study, a simple, fast and reliable LC/MS/MS method has been developed to determinate both isomers simultaneously in rat plasma samples to support the study of disposition kinetics of SU5416. This method is sensitive (limit of quantitation (LOQ = 0.5 ng/mL)), reproducible and has a wide linear range (0.5-2500 ng/mL). There was no conversion between E- and Z-isomer during sample preparation procedure and sample determination with LC/MS/MS. Experimental results proved that SU5416 and SU5886 have identical detection response. Therefore, SU5416 (Z-isomer) was used successfully as analytical standard for SU5886 (E-isomer). This method has been applied to rat plasma samples obtained from a pharmacokinetic study. This study underscores the use of LC/MS/MS technique for bioanalytical methods where analytical standards are not available and analytes are interconvertible. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 4 条
[1]  
Fong TAT, 1999, CANCER RES, V59, P99
[2]   Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors [J].
Hamby, JM ;
Showalter, HDH .
PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :169-193
[3]  
SHAWVER LK, 1999, AM SOC CLIN ONCOLOGY, P29
[4]  
SONG L, 1998, J MED CHEM, V41, P2588